PMID- 33860750
OWN - NLM
STAT- MEDLINE
DCOM- 20210617
LR  - 20210617
IS  - 0946-1965 (Print)
IS  - 0946-1965 (Linking)
VI  - 59
IP  - 6
DP  - 2021 Jun
TI  - Relative efficacy and safety of secukinumab and guselkumab for the treatment of 
      active psoriatic arthritis: A network meta-analysis.
PG  - 433-441
LID - 10.5414/CP203906 [doi]
AB  - OBJECTIVE: To determine the relative effectiveness and safety of doses of 
      secukinumab and guselkumab in patients with active psoriatic arthritis (PsA). 
      MATERIALS AND METHODS: A Bayesian network meta-analysis was performed 
      incorporating data from randomized controlled trials (RCTs) to evaluate the 
      effectiveness and safety of secukinumab 150 mg, secukinumab 300 mg, and 
      guselkumab 100 mg every 4 weeks (Q4W) and guselkumab every 8 weeks (Q8W). 
      RESULTS: Six RCTs, including 2,385 patients, fulfilled the inclusion criteria. 
      The surface under the cumulative ranking curve (SUCRA) revealed that secukinumab 
      300 mg had the highest probability of reaching a 20% American College of 
      Rheumatology (ACR20) response rate, followed by secukinumab 150 mg, guselkumab 
      100 mg Q4W, guselkumab 100 mg Q8W, and placebo. The ACR50 response rate revealed 
      the same distribution pattern as the ACR20 response rate. The SUCRA rating, 
      dependent on the psoriasis area and severity index of at least 75% (PASI75) 
      response rate, showed that guselkumab 100 mg Q4W had the highest possibility of 
      achieving the PASi75 response, followed by guselkumab 100 mg Q8W, secukinumab 300 
      mg, secukinumab 150 mg, and placebo. Safety analyses focused on serious adverse 
      events (SAEs), adverse events (AEs), and withdrawals attributable to AEs that did 
      not have statistically relevant variation in the respective intervention 
      categories. CONCLUSION: Based on the ACR20 and ACR50 response rates, secukinumab 
      300 mg had the strongest response effectiveness, whereas guselkumab 100 mg Q4W 
      was the most effective treatment strategy for PsA based on PASI75. However, there 
      was little disparity between the treatment options with regard to SAEs.
FAU - Song, Gwan Gyu
AU  - Song GG
FAU - Lee, Young Ho
AU  - Lee YH
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - Germany
TA  - Int J Clin Pharmacol Ther
JT  - International journal of clinical pharmacology and therapeutics
JID - 9423309
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antirheumatic Agents)
RN  - 089658A12D (guselkumab)
RN  - DLG4EML025 (secukinumab)
SB  - IM
MH  - Antibodies, Monoclonal/adverse effects
MH  - Antibodies, Monoclonal, Humanized
MH  - *Antirheumatic Agents/adverse effects
MH  - *Arthritis, Psoriatic/drug therapy
MH  - Humans
MH  - Network Meta-Analysis
MH  - Treatment Outcome
EDAT- 2021/04/17 06:00
MHDA- 2021/06/22 06:00
CRDT- 2021/04/16 08:41
PHST- 2021/05/11 00:00 [accepted]
PHST- 2021/04/17 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2021/04/16 08:41 [entrez]
AID - 187910 [pii]
AID - 10.5414/CP203906 [doi]
PST - ppublish
SO  - Int J Clin Pharmacol Ther. 2021 Jun;59(6):433-441. doi: 10.5414/CP203906.